91Â鶹ÌìÃÀ

Alexander McAdam, M.D., Ph.D., D(ABMM), is the Director of Infectious Diseases Diagnostic Laboratory and an associate professor of pathology at Harvard Medical School. He is the 91Â鶹ÌìÃÀ President-Elect and a fellow of the American Academy of Microbiology. McAdam has presented talks at the General Meeting of the American Society for Microbiology, the Laboratory Medicine meeting of the Academy of Clinical Laboratory Physicians and Scientists, the Annual Meeting of the Association of Molecular Pathology and IDWeek. He has published over 150 papers and has authored chapters on clinical microbiology in Harrison’s Principles of Internal Medicine, Robbins and Cotran Pathologic Basis of Disease, Principles of Pharmacology, and Molecular Microbiology: Diagnostic Principles and Practice. He is a volume editor of the Manual of Clinical Microbiology and the Editor in Chief of the Journal of Clinical Microbiology.

Vaughn Cooper, Ph.D., is an evolutionary biologist and microbiologist. He is currently professor of microbiology and molecular genetics, and computational and systems biology, at the University of Pittsburgh School of Medicine. He co-founded and is Director of the (CEBaM), which catalyzes research and education at the interface of these disciplines. He’s also a fellow of the American Academy of Microbiology and, prior to being elected as a member of the 91Â鶹ÌìÃÀ Board of Directors, was Chair of the Council for Microbial Sciences.

Cooper received his bachelor’s degree from Amherst College and his Ph.D. in 2000 from Michigan State University, under the mentorship of Richard Lenski, Ph.D. At MSU, he studied the evolution of specialization within the E. coli long term evolution experiment. Cooper was a postdoctoral fellow of the Michigan Society of Fellows at the University of Michigan, where, along with John LiPuma, M.D., he studied pathogen evolution within the cystic fibrosis airway. He was an assistant and associate professor at the University of New Hampshire from 2004-2015, moving to the University of Pittsburgh in 2015.

Today, the Cooper laboratory studies how potential pathogens (e.g., bacteria such as Burkholderia, Pseudomonas, Acinetobacter and some viruses) evolve to adapt to new hosts and environments. Other major interests include how and why evolution in biofilms differs from well-mixed conditions, the evolution of antimicrobial resistance and why genome regions mutate and evolve at different rates. To enable these studies the lab runs a genomic core tailored to efficient microbial genome sequencing and bioinformatic analyses that aims to identify genetic causes of adaptation and/or drug tolerance during infections.

A broader goal of the Cooper lab is to share the wonder and power of evolutionary biology through outreach and mentorship. The lab's  program provides authentic research experiences and essential learning of evolution, microbiology and genetics through weeklong experiments in the classroom. EvolvingSTEM engages more than 1500 students annually in grades 6-16 and significantly improves student learning and attitudes toward STEM.

Theresa M. Koehler, Ph.D., is Chair Emerita of the Department of Microbiology and Molecular Genetics at McGovern Medical School, University of Texas-Houston Health Science Center. As part of the 91Â鶹ÌìÃÀ leadership team, Koehler is enthusiastic about implementing 91Â鶹ÌìÃÀ’s Strategic Roadmap, which is designed to empower microbial scientists to shape the field, connect global stakeholders and ensure the societal impact of the microbial sciences. She is also committed to enhancing membership engagement as 91Â鶹ÌìÃÀ moves forward in its many missions as one of the most impactful professional scientific societies in the world.

Koehler earned a B.S. at Virginia Tech in biology and M.S. and Ph.D. degrees in microbiology at the University of Massachusetts, Amherst. Following postdoctoral work at Harvard Medical School, Koehler joined the newly-formed Department of Microbiology at the Univ. of Texas–Houston Medical School (now McGovern Medical School) as an assistant professor. She served as professor and chair of the department from 2011-2022.

Koehler is an internationally recognized anthrax expert, and her NIH-funded research program on Bacillus anthracis spanned more than 30 years. She is a fellow of the American Academy of Microbiology and a fellow of the American Association for the Advancement of Science. Koehler’s NIH service has included chairing the bacterial pathogenesis study section and membership and chair positions on several special emphasis grant review panels. She has chaired numerous national and international scientific conferences and served on the editorial board of multiple journals. Koehler served as President of the Association of Medical School Microbiology and Immunology Chairs, and she has been a member of several advisory boards for state and federal science committees, including the National Science Advisory Board for Biosecurity. Throughout her career, Koehler has been passionate about graduate student, medical student and postdoctoral fellow training. She served as the Director of an NIH T32 training grant and is an awardee of the Paul E. Darlington Award from the M.D. Anderson UTHealth Graduate School for Biomedical Sciences for outstanding mentoring of graduate students.

Dr. Robin Patel is currently a professor of medicine and a professor of microbiology, the Elizabeth P. and Robert E. Allen Professor of Individualized Medicine, co-director of the Clinical Bacteriology Laboratory, director of the Infectious Diseases Research Laboratory and chair of the Division of Clinical Microbiology at the Mayo Clinic.

She is board certified in infectious diseases, as well as medical and public health microbiology. Patel’s research, supported by the National Institutes of Health (NIH), focuses on clinical bacteriology diagnostic testing, antimicrobial resistance and microbial biofilms. She has published over 500 peer-reviewed manuscripts and has delivered numerous national and international presentations.

In addition to her positions at the Mayo Clinic, Patel has been a member of the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) Council, and is the director of the NIH-supported Laboratory Center for the Antibacterial Resistance Leadership Group (ARLG), an advisor to the Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing, a member of the American Board of Pathology Medical Microbiology and Clinical Pathology for ABPath CertLink^TM Test Development and Advisory Committees, and an associate editor of Journal of Clinical Microbiology and Clinical Infectious Diseases. She is also a past chair of the U.S. Medical Licensing Examination Microbiology and Immunology Test Material Development Committee and a current member of a U.S. Medical Licensing Examination Item Review Group.

Patel is a fellow of the American Academy of Microbiology, co-chair of the 91Â鶹ÌìÃÀ Microbe 2016-2018 Program Planning Committee and 91Â鶹ÌìÃÀ Past President (Presidency: July 2019-June 2020). 

Victor DiRita, Ph.D., is the Rudolph Hugh Endowed Chair in Microbial Pathogenesis and Chairman of the Department of Microbiology & Molecular Genetics at Michigan State University. His lab studies molecular mechanisms of bacterial pathogens, with particular focus on gut pathogens Vibrio cholerae and Campylobacter jejuni.

DiRita also serves as Chair of the 91Â鶹ÌìÃÀ Membership Board and Editor of the Journal of Bacteriology. He asks you to check out all the great things that the American Society for Microbiology has to offer, to join if you are not a member and to renew if you are! DiRita also invites you to follow him on .

Stefano Bertuzzi, Ph.D., MPH, is the Chief Executive Officer of the American Society for Microbiology (91Â鶹ÌìÃÀ). Bertuzzi has wide experience in science policy and scholarly publishing. Prior to joining as the CEO of 91Â鶹ÌìÃÀ, Bertuzzi was the Executive Director at the American Society for Cell Biology for 3 years and was a senior scientific executive at the National Institutes of Health (NIH), where he served as Director of the Office of Science Policy, Planning, and Communications at the National Institute of Mental Health and as a science policy advisor to the NIH Director, Dr. Elias Zerhouni. He also served as Director of Neurogenetic Laboratory at the Dulbecco Institute as a Telethon Scientist in Milan, Italy.

Bertuzzi received his Ph.D. in Molecular Biotechnology from the Università Cattolica del Sacro Cuore of Milan, Italy with a fellowship in the Microbiology Institute, and his Master’s in Public Health (MPH) from the Bloomberg School of Public Health at the Johns Hopkins University in Baltimore with a specialization in health policy.

Throughout his career, Bertuzzi led the U.S. government negotiations with the European Union (EU) to achieve funding reciprocity between the NIH and the EU. He also worked with the Obama White House to develop an information system to capture the benefits of scientific investments made during the Great Recession of 2008. He is one of the leaders who spearheaded the Declaration on Research Assessment (DORA) to fight the misuse of journal impact factor metric. He contributed to the NIH revision of the peer review system and to the development of the key public access policy for NIH funded research, which started the Open Access movement in scholarly publishing.

Most recently, Bertuzzi led 91Â鶹ÌìÃÀ's efforts to address the SARS-CoV-2 pandemic. This included working directly with the White House COVID-19 Task Force, the Food and Drug Administration (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) to increase access to diagnostic testing supplies and address roadblocks to coronavirus testing. Bertuzzi penned a  and an  outlining testing roadblocks and emphasizing the need for microbiologists and other scientists to support clinical laboratories to help contain the pandemic.

He has authored numerous research publications, editorials and science policy pieces in top journals and is recipient of many national and international awards. Bertuzzi is a thoughtful leader in science, a fellow of the prestigious Aspen Institute and a member of the Cosmos Club. In 2020, the President of the Italian Republic bestowed upon Bertuzzi the title of Knight of the Order of the Star of Italy, one of the highest honors in the Italian Republic.

Michelle Dziejman, Ph.D., earned her B.S. in biology: microbiology from the University of Rochester and her Ph.D. in microbiology and molecular genetics from the University of Pennsylvania. A series of fortunate events allowed her to conduct her thesis work at Harvard Medical School, where she first began working with Vibrio cholerae. Interested in the (at that time emerging) field of host-pathogen interactions, a postdoctoral fellowship at Massachusetts General Hospital facilitated an immersive experience in molecular immunology.

Developing genomics-based projects during a return to Harvard Medical School laid the groundwork for a faculty position and full-circle return to Rochester, N.Y. Dziejman is currently an associate professor of microbiology and immunology at the University of Rochester Medical Center, where her laboratory studies the pathogenic mechanisms of type III secretion system-positive V. cholerae strains. She also serves as director for the microbiology M.S. program and course director for "Mechanisms of Microbial Pathogenesis."

Michael S. Gilmore, Ph.D., is the chief scientific officer at Massachusetts Eye and Ear/Massachusetts General Brigham and a senior scientist at Massachusetts Eye and Ear. 

Joanna Goldberg, Ph.D., is a professor in the Department of Pediatrics at Emory University School of Medicine and holds a secondary appointment in the Department of Microbiology & Immunology. She was awarded the 2012 91Â鶹ÌìÃÀ Graduate Microbiology Teaching Award.

Prior to joining Emory, she was a professor in the Department of Microbiology, Immunology and Cancer Biology at the University of Virginia and at the Channing Laboratory, Brigham & Women’s Hospital, Department of Medicine at Harvard Medical School. She received her B.A. in biology from Boston University and Ph.D. in microbiology and immunology from the University of California at Berkeley.

Goldberg has had continuous NIH funding for research on bacterial pathogens associated with life-threatening lung infections in individuals living with cystic fibrosis, particularly Pseudomonas aeruginosa. She studies the synthesis and regulation of surface antigens, including polysaccharides and protein adhesins, their role in infection and as potential antimicrobial and vaccine targets.

Goldberg was awarded the 91Â鶹ÌìÃÀ Raymond W. Sarber Fellowship Award as a graduate student. As examples of her 91Â鶹ÌìÃÀ involvement, she is a member of 91Â鶹ÌìÃÀ’s Council on Microbial Sciences (COMS), she was chair of Division D, councilor for Division B, Chair of the 91Â鶹ÌìÃÀ Career Development Committee, Chair of the 91Â鶹ÌìÃÀ Conferences Committee and President of the 91Â鶹ÌìÃÀ Virginia Branch.

Sue Ishaq, Ph.D., is an associate professor of microbiomes at the University of Maine, in the School of Food and Agriculture. She received her doctorate in animal, nutrition and food science from the University of Vermont in 2015, where her graduate study focused on the rumen microbiology of the moose. She held post-doctoral positions in bioinformatics and microbial ecology at Montana State University, and a research faculty position at the University of Oregon.

Over the years, Ishaq's research has gone from wild animal gut microbiomes, to soils, to buildings, and back to the gut. Since 2019, her lab in Maine has focused on host-associated microbial communities in animals and humans and, in particular, how host and microbes interact in the gut and can be harnessed to reduce inflammation.

Ishaq is the founder of the Microbes and Social Equity working group, an international research community which formed to examine, publicize and promote a research program on the reciprocal impact of social inequality and microbiomes, both human and environmental. Ishaq organizes an annual speaker series, annual virtual symposium and was the lead editor on a microbes and social equity special collection with the 91Â鶹ÌìÃÀ mSystems journal.

Michael D. L. Johnson, Ph.D., received an A.B. in Music from Duke University before obtaining his Ph.D. in biochemistry and biophysics at the University of North Carolina at Chapel Hill. After completing his dissertation in bacterial motility and attachment, he went to St. Jude Children’s Research Hospital in the Department of Infectious Disease to study how bacteria process nutrients, specifically metals, during bacterial infections. He then worked in the department of immunology, studying newly discovered ways that the body eliminates harmful pathogens.

During his postdoctoral fellowship, he also founded Science Sound Bites, a science podcast for kids. Currently, Johnson is an assistant professor at the University of Arizona in the Department of Immunobiology, where he studies mechanisms of metal toxicity in bacteria. In short, he’s killin’ it with copper.

Johnson is active in science outreach through events like , DNA Day, The . He is also active in minority scientific affairs through the American Society for Microbiology and can be found online on X .

Dr. Kellogg grew up on a charter boat in the Virgin Islands with the Caribbean Sea as her backyard, so it was no wonder she pursued a career in marine biology. Chris is a research microbiologist with the U.S. Geological Survey and currently leads an environmental microbiology laboratory specializing in coral microbial ecology. Her research on tropical corals has taken her to the Florida Keys, Caribbean, Hawaii and American Samoa, leading her friends to say that she specializes in ‘resort microbiology.’

Chris has been working in deepwater coral ecosystems since 2004 and considers herself extremely lucky to have had the privilege of visiting them personally using the Delta, Johnson-Sea-Link and Alvin submersibles. She has authored more than 30 peer-reviewed papers as well as a number of book chapters and has given invited keynote talks on both her aerosol microbiology and deep-sea coral microbial work. Chris served as a judge for the $2-million dollar Wendy Schmidt Ocean Health XPRIZE competition to design more accurate pH meters for the deep ocean and the $7-million dollar Shell Ocean Discovery XPRIZE to develop autonomous undersea mapping technologies. She was elected to the Council Policy Committee of the American Society for Microbiology (2012–2016), playing an active role in revamping the communication and governance structures of the organization. Chris is active in shaping the direction of microbiome research in the U.S., having represented the Department of Interior on the Federal Microbiome Interagency Working Group and being a part of the National Microbiome Data Collaborative.

Federico Sisti, Ph.D., is an independent researcher at the Institute of Biotechnology and Molecular Biology (IBBM) of the National Scientific and Technical Research Council (CONICET). He obtained his Ph.D. from the Faculty of Exact Sciences at the National University of La Plata. Since then, he has focused his research on the infection process of Bordetella species. In recent years, Sisti’s laboratory has concentrated on studying the role of the second messenger c-di-GMP in the infection processes of Bordetella bronchiseptica and Bordetella pertussis.

Sisti adopts a collaborative approach to research, aiming not only to uncover new mechanisms of pathogenesis, but also to provide comprehensive training for his students. He serves as an associate professor at the Faculty of Exact Sciences, where he engages in weekly teaching activities. This role challenges him to stay updated and in touch with the new generation of scientists.

Sisti has been involved with 91Â鶹ÌìÃÀ since the start of his career and is excited to take on this new challenge. Before joining the 91Â鶹ÌìÃÀ Board, he served as Secretary of the Argentine Society for Biochemical Research, one of the oldest biological science societies in Argentina.

Vincent Young, Ph.D., is the William Henry Fitzbutler Collegiate Professor in Internal Medicine/Infectious Diseases Division and Microbiology & Immunology at the University of Michigan Medical School. He received his undergraduate degree from the Massachusetts Institute of Technology in 1985 and received his M.D. and Ph.D. in microbiology and immunology from Stanford University in 1992. He completed clinical training in internal medicine and infectious diseases at the Massachusetts General Hospital. After an initial faculty position at Michigan State University, he joined the University of Michigan in 2007.

Young has a long-standing interest in the pathogenesis of bacterial infections of the gastrointestinal tract and the role of the normal microbiota in human health and disease. As part of the NIH Human Microbiome Project, Young led a team that studied the role of the microbiome in inflammatory bowel disease. Current research in the Young Lab includes a "team science" effort to understand the pathogenesis Clostridium difficile infection by an integrated approach combining clinical research, bacterial genomics, microbial ecology and immunology/host response projects.

Young also is leading a group of investigators that is developing the use of stem cell-derived intestinal organoids as a novel alternative model system for the study of enteric disease agents.